Newsroom

News

New antibiotics are urgently needed in the fight against multi-resistant bacteria. The recently discovered darobactin is a potential candidate with resistance-breaking properties. This substance shows very good antimicrobial activity against some of the most problematic hospital germs. However, so far darobactin could only be produced in relatively small quantities, making detailed investigation and further development difficult. A team led by Dr Sebastian Groß from the Department of Microbial Natural Products at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) in Saarbrücken has now addressed this problem. The scientists published their results in the journal Chemical Science.

31.08.2021

HIPS

News

Data Scientists are in demand on the job market: all 18 Helmholtz Centers have already advertised several positions calling for skills in AI methods in 2021.

30.08.2021

HZI Campus

Konzept für die nachhaltige Entdeckung und Entwicklung neuer Antibiotika

News

Increasingly insensitive to standard drugs: Multi-resistant pathogens are spreading worldwide and even in the near future could threaten the safe treatment of deadly infectious diseases. However, the urgent demand for new antimicrobial agents is offset by a glaring lack of investment into their research. In an article in Nature Reviews Chemistry, the international research alliance IRAADD, which is coordinated by HZI researcher and HIPS director Prof Rolf Müller, presents forward-looking strategies that could be used to solve the problem. Scientists at the German Center for Infection Research (DZIF) are playing a leading role.

20.08.2021

HIPS

Arme und Hände die auf einer Tastatur liegen

News

The Alexander von Humboldt Foundation has selected Prof Claus-Michael Lehr as a scout within the Henriette Herz Programme.This award allows him to select three young scientific talents from abroad who will work at HIPS for one year as Alexander von Humboldt fellows. In the interview, he explains how this came about and how important international collaboration in science is to him.

11.08.2021

HIPS

News

The oral cavity germ Fusobacterium nucleatum is known to speed up the growth of human carcinomas, for example in the intestine or breast. In a joint study, the Helmholtz Institute for RNA-based Infection Research (HIRI), a site of the Helmholtz Centre for Infection Research (HZI), and the Julius Maximilians University (JMU) in Würzburg, Germany, have now mapped the RNA molecules of five clinically relevant strains of this adaptable bacterium. The findings could help develop new therapies for various cancers. The results of the research have been published in the journal Nature Microbiology.

02.08.2021

HIRI

Rasterelektronenmikroskopische Aufnahme einer menschlichen B-Zelle

News

Immunosuppressed patients often cannot build up good protection after a vaccination because the necessary cells of the immune system function less well or are not present at all. This has been studied especially in the drug therapy of rheumatoid arthritis. Scientists from TWINCORE and the Hannover Medical School (MHH) have now published in the journal Annals of the Rheumatic Diseases the circumstances under which this group of people can nevertheless be successfully vaccinated. Based on their data, they recommend a promising strategy for the COVID-19 vaccination of rheumatism patients who are treated with the drug Rituximab. The TWINCORE-Centre for Experimental and Clinical Infection Research is a joint institution of the MHH and the Helmholtz Centre for Infection Research (HZI) in Braunschweig.

15.07.2021

TWINCORE

Back to the first page
...
53
54
55
56
...
150

HZI in the media

Beisel at Germany's Helmholtz Institute for RNA-based Infection Research in Würzburg and Dirk Heinz at the Helmholtz Center for Infection

07.01.2026

News Medical

... basierte Infektionsforschung (HIRI) in Würzburg nachweisen. Gemeinsam mit dem Braunschweiger Helmholtz-Zentrum für Infektionsforschung ...

07.01.2026

DeutschesGesundheitsPortal

consisting of Hannover Medical School (MHH), the Helmholtz Centre for Infection Research (HZI) in Braunschweig, and the Leibniz Institute in

07.01.2026

Trading View

... haben nun die Studienautoren vom HIRI ‒ einem Standort des Braunschweiger Helmholtz-Zentrums für Infektionsforschung (HZI) in ...

02.01.2026

Biermann Medizin

... bis zur Medikamentenentwicklung", sagt Josef Penninger, wissenschaftlicher Geschäftsführer des HZI und Leiter der Abteilung Innovative ...

30.12.2025

Tagesschau

Erkrankungen. Eine Arbeitsgruppe des TWINCORE Helmholtz Zentrum für Infektionsforschung ( HZI ) und der Medizinischen Hochschule Hannover ( ...

30.12.2025

Deutsches Ärzteblatt

Forschungsteam um Tobias Gulder, Abteilungsleiter am Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS), ist es ...

29.12.2025

Biermann Medizin

... des Leibniz Lungenzentrums Borstel, des Helmholtz-Instituts für Pharmazeutische Forschung Saarland sowie weiterer wissenschaftlicher ...

29.12.2025

Das PTA Magazin

Dr. Rolf Müller, Managing Director of Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), were both named laureates of the

22.12.2025

Research Information

... ein Interview mit Josef Penninger geführt . Er ist wissenschaftlicher Geschäftsführer des Helmholtz-Zentrum für Infektionsforschung in ...

21.12.2025

T3N

Forschende vom Würzburger Helmholtz-Institut für RNA-basierte Infektionsforschung (HIRI), einem Standort des Braunschweiger Helmholtz- ...

17.12.2025

Verband Deutscher Biologen e.V.

Finanzierungsmöglichkeiten fehlen.

Josef Penninger, wissenschaftlicher Geschäftsführer des Helmholtz-Zentrums für Infektionsforschung (HZI)

16.12.2025

MedMedia

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.